Book Description
The Low GI Diet Revolution is the only science-based diet that is proven to help you lose up to 10 percent of your current weight and develop a lifetime of healthy eating habits that can protect you from illness and disease. Synthesizing over 20 years of ground-breaking research on carbohydrates and the glycemic index, the authors of the New York Times best-selling New Glucose Revolution series show you how to make "smart carb" food choices for every meal that will satisfy your hunger, increase your energy levels, and eliminate your desire to eat more than you should. In addition, The Low GI Smart Carb Diet features an effective 12-week action plan with food, exercise, and activity goals for each week and a maintenance program to help you solidify your new eating habits and avoid regaining weight. The result: A slimmer, stronger, healthier you-for the rest of your life.
Customer Reviews:
Worth the time to read........2006-08-14
Fact based book that has helped me understand the Glycemic Index and how to eat so that I am not hungry within 15 minutes after eating.
Excellent book on how to eat.......2006-05-12
This book is an excellent one for understanding how and what to eat. For those of us who may have grown up in families where it was always meat and potatoes until full, with an occasional soggy veg thrown in, this book is great at helping you learn what it means to eat in a healthy way that allows you to be full and lose weight if you need to. It even addresses exercise in ways that most people can do easily at home.
This is the first book on eating (or dieting) that I've really understood because it makes sense. No alarm bells went off in my head about eating this way, no doubt that I could sustain this way of eating for life, and no worrying about how much this was going to cost in specially purchased foods or gym memberships.
The reason I gave this book 4 stars instead of 5 is that the recipes are pretty far out there and contain a lot of ingredients not readily available in the average kitchen. Plus, the cooking involved is probably something that would reduce the chance of anyone trying too many of these recipes.
It's entirely possible though to use types of foods that are low GI and imaginatively combine them in ways you're familiar with cooking and eating.
I would strongly recommend this book despite the difficult recipes at the end. The remainder of the book is excellent and will be one which makes sense to anyone who reads it. May we all achieve / maintain our desired weight and be healthier in the process!
Very informative book on controlling glycemia.......2006-03-15
What recommended this book to me was that the authors were pioneers in the concept of the glycemic index. I knew intuitively that this concept mattered, but till recently all I knew was too many carbs were bad. But this is one of the books that corrects that notion to say that what matters is how directly a carbohydrate enters the bloodstream. Too directly means a load on the pancreas, perhaps an overreaction, perhaps hypoglycemia, and over time insulin resistance. The book not only explains that lucidly but then it moves on to explain how a person can revise his diet so that there is a healthy percentage of carbs without these adverse results. I can't say if the book is superior to others, but I can say that it contains useful information expressed in understandable terms.
The Low GI Diet Revolution.......2005-08-13
IFound this book very helpful. for I am a personal trainer and I have also beleive in the GI and My clients have enjoyed it too.
I found it easy to understand and easy to follow the 12 week Plan .
I have seen the results and it has only been about six weeks
Thanking you Gae Price (New Zealand)
The Low GI Diet Revolution-The Definitive Science-Based Plan.......2005-06-17
In my opinion, the low GI diet is a healthy diet not only for weight loss but for people who want to delay the onset of diseases such as Type 2 diabetes. The statistics concerning GI values of common food serves as an excellent resource and the suggested menus are easy to follow.
Book Description
Markets in Motion is a graphical overview of the economic conditions and events that have influenced the U.S. stock market since 1900. Decade by decade, you'll examine how different economic and policitcal environments can be directly correlated to stock market movements. Each decade features graphs displaying the performance of the Dow Jones Average, the Dow Jones price to dividend ratio, industrial production, money supply, consumer price index, T bill rate, and the Discount rate. Embedded on the graphs are short descriptions of important political, economic, and historical events. Use this information to reference similar environments today and gain an edge in determining the future direction of the market.
Customer Reviews:
No bad..........2007-01-04
...but I wasn't particularly impressed. Investors Business Daily has nice wall charts with all this information. Much nicer. Cheers!
Average customer rating:
|
The Theory of the Cost-of-Living Index
Robert A. Pollak
Manufacturer: Oxford University Press, USA
ProductGroup: Book
Binding: Hardcover
 General
| Popular Economics
| Business & Investing
| Subjects
| Books
Microeconomics
| Economics
| Business & Investing
| Subjects
| Books
Statistics
| Economics
| Business & Investing
| Subjects
| Books
Theory
| Economics
| Business & Investing
| Subjects
| Books
Production & Operations
| Management & Leadership
| Business & Investing
| Subjects
| Books
General
| Sociology
| Social Sciences
| Nonfiction
| Subjects
| Books
All Titles
| Qualifying Textbooks - Fall 2007
| Stores
| Books
ASIN: 0195058704 |
Book Description
Providing a valuable resource for government economists, academics, and research libraries, this volume contains twelve papers by Robert Pollak--four previously unpublished--that explore the theory of the cost of living index. In addition to Pollak's classic paper, "The Theory of the Cost of Living Index," the volume includes papers on subindexes, the intertemporal cost of living index, welfare comparisons and equivalence scales, the social cost of living index, the treatment of "quality," and consumer durables in the cost of living index.
Average customer rating:
|
Consumer Price Index Manual: Theory And Practice
Manufacturer: International Labour Office
ProductGroup: Book
Binding: Paperback
General
| Popular Economics
| Business & Investing
| Subjects
| Books
Microeconomics
| Economics
| Business & Investing
| Subjects
| Books
Research
| Marketing
| Marketing & Sales
| Business & Investing
| Subjects
| Books
General
| Reference
| Business & Investing
| Subjects
| Books
Consumer Guides
| Reference
| Subjects
| Books
General
| Reference
| Subjects
| Books
ASIN: 922113699X |
Average customer rating:
- Excellent book to see if your salary keeps up with inflation
|
How Much Is That in Real Money?: A Historical Price Index for Use As a Deflator of Money Values in the Economy of the United States
John J. McCusker
Manufacturer: American Antiquarian Society
ProductGroup: Book
Binding: Paperback
General
| Popular Economics
| Business & Investing
| Subjects
| Books
Microeconomics
| Economics
| Business & Investing
| Subjects
| Books
Money & Monetary Policy
| Economics
| Business & Investing
| Subjects
| Books
Public Finance
| Economics
| Business & Investing
| Subjects
| Books
Theory
| Economics
| Business & Investing
| Subjects
| Books
General
| United States
| Americas
| History
| Subjects
| Books
General
| Encyclopedias
| Reference
| Subjects
| Books
ASIN: 0944026338 |
Customer Reviews:
Excellent book to see if your salary keeps up with inflation.......1998-09-13
Excellent statistical narrative that will allow you to gauge your home appreciation or weekly salary wrt the consumer price index. The results can be quite fascinating. For instance the 35 cent a gallon gasoline in 1973 should be 1.35 today. Or a 15,000 home in 1960 should be 87,000 today. For those penny pinchers like myself who are always trying to second guess the platitudes of our company pay raise proposals, this book will allow you to keep em straight. The primary shortcoming with this book though is that it ends in 1991. A revision really does need to be published yearly or otherwise each additional year after 1991 most be interpolated individually. Mr McCusker please update next year.
Average customer rating:
|
1998 Revision Of The Consumer Price Index
Deborah P. Klein
Manufacturer: Diane Pub Co
ProductGroup: Book
Binding: Paperback
General
| Law
| Subjects
| Books
Reference
| Law Practice
| Law
| Subjects
| Books
Reference
| Law Practice
| Law
| Professional & Technical
| Subjects
| Books
ASIN: 0788144979 |
Book Description
This digital document is an article from World Economic Outlook, published by International Monetary Fund on September 1, 2002. The length of the article is 1797 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Advanced economies: GDP deflators and consumer prices.(Illustration)
Publication:
World Economic Outlook (Magazine/Journal)
Date: September 1, 2002
Publisher: International Monetary Fund
Page: 179(1)
Article Type: Illustration
Distributed by Thomson Gale
Book Description
This digital document is an article from World Economic Outlook, published by International Monetary Fund on May 1, 2001. The length of the article is 1566 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Advanced Economies: GDP Deflators and Consumer Prices.(Statistical Data Included)
Publication:
World Economic Outlook (Magazine/Journal)
Date: May 1, 2001
Publisher: International Monetary Fund
Page: 177
Article Type: Statistical Data Included
Distributed by Thomson Gale
Book Description
This digital document is an article from Atlantic Economic Journal, published by Atlantic Economic Society on September 1, 1990. The length of the article is 3650 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: An analysis of the potential of price reform on food production in Poland.
Author: Julian T. Krzyzanowski
Publication:
Atlantic Economic Journal (Refereed)
Date: September 1, 1990
Publisher: Atlantic Economic Society
Volume: v18
Issue: n3
Page: p74(8)
Distributed by Thomson Gale
Book Description
A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries
To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors.
George Wolff (St. Pete Beach, FL) is a successful consultant advising clients who are investing in biotech stocks. He has assessed well over 150 biotech companies and has issued a number of valuable white papers that have charted the success of the hottest biotech companies.
Customer Reviews:
Ambitious try.......2005-12-02
As the title of the book suggested, Wolff ambitiously aimed to write a 'bible' for biotech investors. His ambitious effort fell short. I find the content of the book quite uneven: the scientific background chapters are relatively well written, but some of the computer analogy seems redundant & distracting; the investment perspective chapters are slightly disappointing, as I do not see the merit of categorizing biotech firms based on market capitalization, & the case studies can be more systematically organized to better illustrate the underlying arguments.
Given the highly complicated nature of the biotech industry, I can imagine it is challenging, if not impossible, for any author to write a 'bible' for biotech investors. Especially, when biotech is a hardcore science, while investment can be considered as an art rather than a science.
Biotech is a small market niche with strong growth potential.......2005-03-21
Biotech investors may be able too realize profits by recognizing the Biotech sector is an industry that will take several decades to mature. Biotech has taken two decades of research for the first wave of products to start hitting the market. In 2000, biotech had 30,000 patients submitted more than all the years combined of 16,000 patients total. Individual investors have the opportunity to own some of tomorrow's giants, if they take a position early and wait as the market gyrates and finally recognizes a great emerging giant.
Biotech is a small market niche and the growth potential is strong and investors provide the capital for growth and expansion in this sector. Investors have shifted investment strategies away from research information collection investment too product oriented investment. One expert estimates the cost to bring a drug to market at $1.5 billion and 15 years of research and development effort.
The author segments the Biotech sector into four tiers: Tier 1 - biotech companies generating a substantial revenue flow and usually having high PE ratios suggesting high investor expectations for results and offer greater reliability because of their revenue flow: Amgen created Epogen, a drug that cause blood regeneration yielding profits of over a billion dollars a year and Biogen created three interferon drugs for (Hepatitis C, Cancer and MS); Tier 2 - biotech companies representing a long term growth investment. These types of biotech companies have strong developed research capabilities, a strong drug pipeline, a good array of partners and alliances, royalty revenue, and greater prospects than Tier 1; Tier 3- biotech companies with a promising product line, market capitalization greater than $800 million, in danger of severe loss on product failure or FDA rejection, position for great gains if FDA approved, and represent the major of investment opportunity; Tier 4 - biotech companies that are inexpensive to position in, these are the great bargains and they are characterized as having market capitalization below $800 millions with low trade volume and risks of liquidity shortages.
Tier 2 companies are attractive because they have products on the market and these products usually take one to two years to realize a gain. Biotech survival depends on having getting more drugs to the trial stage, thus, increasing the likelihood of a profit. Second creating drugs or therapies focused on treating serious or untreatable diseases. Third arranging alliances and partnerships too reduce risk and provide market and development capital. And fourth shorten times for FDA approval.
The author recommends keeping an eye out for simple and inexpensive ways to combat disease. The author warns that biotech is very volatile characterized often with swings reaching between 10 to 30 percent in a day, furthermore, hedges against the risk of loss where gains could be 20-30 percent if FDA approved and 70 percent if reject. The market will not tolerate failure and has punished numerous companies when a product has an adverse effect on a consumer.
The author also points out that often the market will react positively on news driving the price up but sell off in the following months but often the long term pattern demonstrates a positive price acceleration. The author uses a 50 and 200 day moving average to gauge price direction and encourages investors to buy the company not the price. The Biotech sector Beta is effect by the market trends and price can move counter to breakthrough news if the market is moving against price.
BioChips: Affymetrix the leader in "bio chip" technology using a process called hybridization uses a solution containing genetic material bathes the bio chip; the bio chip has tubes contain DNA material for which some of the genes from the genetic solution will attach to or hybridize the tiny probes on the chip; and when scanned by laser, these hybridized probes will glow and will be detected by the computer. The author suggests that the bio chip can not discover all diseases instead it will probably work like this: a physican will have too analyze the patients condition and select a gene probe array that have been designed to look for problems in that particular area of suspected diagnosis.
Genomics: Celera, Geonome Therapeutics, Human Genome Sciences, Hyseq, Incyte Pharmaceuticals, Millenium Pharmaceuticals, Orchid Biosciences, Sequenom, Variagenix, Diversa, Gene Logic, Cura Gen, Myraid Genetics, and Maxygen.
Proteomic Analysis: Celera, Ciphergen Biosystems, Genomic Solutions, Large Scale Biology, Cytogen, and Myraid Genetics.
Monoclonial Antibodies: 70 percent are in clinical trials. Antibodies are proteins with a purpose. The B cell creates an epitome or a mold from the antigens of the foreign bodies. The epitome is used to identify the cell type to attack. The B cell produces the antibodies that attach to the antigens of the foreign cell. The B cell can create only one type o antibody and clone many copies of this strain.
Monoclonial Antibodies: Abgenix, Coulter, Imclone, Immunomedics, Medarex, Neorx, Medimmune, IDEC Pharaceuticals, Immunogen, Gliatech, AVI biopharma, ICOS, Protein Design Labs, and Cytogen
Protein Therapies: Lilly, Genetech, Amgen, Biogen, Cytogen, and Myriad
New Vaccines: Aphton, Chiron, Vical, AVAX, Biomira, Epimmune, Neurocrine Biosciences, Corix, Geron, Cytogen, Aviron, Trimeris, Genzyme, and Vaxgen
Growth Factor: Amgen, Regeneron, Curis, American Biogenetic, Gullford
Tissue Replacement: Regen Phrama, and Regeneration Technologies.
Give this one a miss.......2004-05-19
There is not good book on biotech investing. The Biotech Investor's Bible is poorly written and badly organized. I find the same companies provided as examples again and again. Some of them no longer exist! The risk of this industry was not sufficiently highlighted.
The author groups companies based on market capitalization; I believe that this approach is fundamentally flawed. It runs the risk of feeding right into a mania.
I would like to have seen more comment on the stalwart biotech companies.
I did not learn much from this book. Perhaps that is the point. This area is a challenge.
Overall a disappointing read.......2004-05-17
Successful investing is difficult. Investing in biotech companies can be even more challenging. I did not find this book up to the challenge.
The organization of the book was confusing: the author jumped around from topic to topic. The discussion of the science was fine, but there was not really anything that I could not find from a five minute web search.
I believe if I had calibrated my expectations differently, I may have found value in this text. The example companies are dated. I believe one of them at least no longer exists. Some of the companies classified as biotech companies are really baby pharmaceutical companies.
The tiered approach to differentiating among companies was interesting. It did not clarify for me how I should approach an investment.
The writing style is good, in fact, I found the book easy to read. I have to be blunt, the content was very disappointing.
I do have to remember that when it comes to biotech investing, we're at the crossroads of two difficult activities. I did not find that this book clarified either.
Good but Disorganized.......2003-09-19
This was a difficult book for me to review. I bought it primarily because of the rave reviews on this web site. Overall, I'm glad I did. However, the book fell slightly short of the reviews, hence my 4 star rating. It contained a great deal of interesting and useful information but lacked organization and structure. In that sense, it was indeed a Bible, a collection of articles, rather than a text.
My primary complaint is that the first few chapters were practically devoid of content, offering only hype on how great biotech is. The comparison of biotechnology with the PC industry was also a bit of meaningless hype.
On the positive side, after the reader wades through or skips the first three chapters (unfortunately, I read them), there are numerous valuable bits of information and insight. Particularly valuable are the author's idea of categorizing biotech companies by market capitalization (share price times shares outstanding). This is a useful way of measuring how the market evaluates a company that has no current earnings. Chapters 10 through 15 are a veritable encyclopedia of the different approaches taken by biotech companies, from anti-sense to vaccines. The leading companies in each field are introduced and their prospects briefly reviewed. These chapters were readily useful to the investor and led me to make (so far) successful investments in PDLI and QLTI.
The book is now silghtly dated, having been published in 2001. However, this can be said of any two year old investment book. The reader should certainly do some careful analysis of the current state of any candidate for investment. I actually found the slightly dated nature useful in that it allowed my to judge which companies still looked like winners two years later and which did not.
Advice: Buy the book, skip the first three chapters, and read the rest. Also buy and read Investing in Biotech by David Harper which covers much of the same material in a more orderly manner. (More detail is available in my review of that book.)
Books:
- The New Color of Success: Twenty Young Black Millionaires Tell You How They're Making It
- The New York Times Practical Guide to Practically Everything: The Essential Companion for Everyday Life
- The Office Romance: Playing With Fire Without Getting Burned
- The Portable Business Writer (The English essentials series)
- The Project 50 (Reinventing Work): Fifty Ways to Transform Every "Task" into a Project That Matters!
- The Seven C's of Consulting: The Definitive Guide to the Consulting Process, Second Edition
- Thomson Delmar Learning's Comprehensive Medical Assisting: Administrative and Clinical Competencies (Delmar's Comprehensive Medical Assisting)
- Time Management from the Inside Out, second edition: The Foolproof System for Taking Control of Your Schedule--and Your Life
- Trump: How to Get Rich
- Understanding Bonds & Gilts in a Day (Understand in a Day)
Books Index
Books Home
Recommended Books
- Inequality, Poverty, and Neoliberal Governance: Activist Ethnography in the Homeless Sheltering Indu
- Bound for Oregon
- The Accounting Cycle: A Practical Guide to Accounting Basics
- The Winner's Guide to Casino Gambling: Fourth Edition
- A Guide to the Project Management Body of Knowledge, Third Edition
- Death of a Prankster
- A Rage for Justice: The Passion and Politics of Phillip Burton
- Accounting Principles, with PepsiCo Annual Report, General Ledger Software for Windows
- The Violence of Green Revolution: Third World Agriculture, Ecology and Politics
- Involuntary Witness
The Low GI Diet Cookbook: 100 Simple, Delicious Smart-Carb Recipes-The Proven Way to Lose Weight and Eat for Lifelong Health (Glucose Revolution)
The New Glucose Revolution Shopper's Guide to GI Values 2007: The Authoritative Source of Glycemic Index Values for More than 500 Foods (Glucose Revolution)
The New Glucose Revolution: The Authoritative Guide to the Glycemic Index - the Dietary Solution for Lifelong Health (Glucose Revolution)
The New Glucose Revolution Shoppers' Guide to GI Values 2006: The Authoritative Source of Glycemic Index Values for More than 500 Foods (Glucose Revolution)
The New Glucose Revolution: Low GI Eating Made Easy
